Empagliflozin selected cardiovascular and safety outcomes in routine care: First results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study

被引：0
|
作者：
Patorno, E. [1 ]
Pawar, A. [1 ]
Franklin, J. M. [1 ]
Najafzadeh, M. [1 ]
Deruaz-Luyet, A. [2 ]
Brodovicz, K. G. [3 ]
Sambevski, S. [4 ]
Bessette, L. G. [1 ]
Kulldorff, M. [1 ]
Schneeweiss, S. [1 ]
机构：
[1] Harvard Med Sch, Div Pharmacoepidemiol, Dept Med, Brigham & Womens Hosp, Boston, MA 02115 USA
[2] Boehringer Ingelheim Int GmbH, Corp Dept Global Epidemiol, Ingelheim, Germany
[3] Boehringer Ingelheim Pharmaceut Inc, 90 E Ridge POB 368, Ridgefield, CT 06877 USA
[4] Boehringer Ingelheim Int GmbH, Corp Dept Med, Ingelheim, Germany
来源：
METABOLISM-CLINICAL AND EXPERIMENTAL | 2020年 / 104卷
关键词：
Sodium glucose co-transport inhibitor 2; Healthcare utilization; Diabetic ketoacidosis;
D O I：
10.1016/j.metabol.2019.12.072
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Empagliflozin selected cardiovascular and safety outcomes in routine care: first results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study
    Patorno, E.
    Pawar, A.
    Franklin, J. M.
    Najafzadeh, M.
    Deruaz-Luyet, A.
    Brodovicz, K. G.
    Sambevski, S.
    Bessette, L.
    Kulldorff, M.
    Schneeweiss, S.
    DIABETOLOGIA, 2019, 62 : S329 - S330
  • [2] Empagliflozin Selected Cardiovascular and Safety Outcomes in Routine Care: First Results from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study
    Patorno, Elisabetta
    Pawar, Ajinkya
    Franklin, Jessica
    Najafzadeh, Mehdi
    Deruaz-Luyet, Anouk
    Brodovicz, Kimberly
    Sambevski, Steven
    Bessette, Lily G.
    Kulldorff, Martin
    Schneeweiss, Sebastian
    DIABETES, 2019, 68
  • [3] Empagliflozin selected cardiovascular and safety outcomes in routine care: first results from theempagliflozin comparative effectiveness and safety (EMPRISE) study
    Patorno, Elisabetta
    Pawar, Ajinkya
    Franklin, Jessica M.
    Najafzadeh, Mehdi
    Deruaz-Luyet, Anouk
    Brodovicz, Kimberly G.
    Sambevski, Steven
    Bessette, Lily G.
    Kulldorff, Martin
    Schneeweiss, Sebastian
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 419 - 419
  • [4] Effectiveness and Safety of Empagliflozin in Routine Care: Results from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study
    Htoo, Phyo T.
    Tesfaye, Helen
    Paik, Julie M.
    Wexler, Deborah J.
    Najafzadeh, Mehdi
    Glynn, Robert
    Deruaz-Luyet, Anouk
    Farsani, Soulmaz F. Fazeli
    Koeneman, Lisette
    Schneeweiss, Sebastian
    Patorno, Elisabetta
    DIABETES, 2022, 71
  • [5] Effectiveness and safety of empagliflozin in routine care: Results from the empagliflozin comparative effectiveness and safety (emprise) study
    Htoo, Phyo
    Tesfaye, Helen
    Paik, Julie
    Wexler, Deborah
    Najafzadeh, Mehdi
    Glynn, Robert
    Deruaz-Luyet, Anouk
    Farsani, Soulmaz
    Koeneman, Lisette
    Schneeweiss, Sebastian
    Patorno, Elisabetta
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 40 - 41
  • [6] Effectiveness and safety of empagliflozin in routine care patients: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study
    Patorno, Elisabetta
    Pawar, Ajinkya
    Wexler, Deborah J.
    Glynn, Robert J.
    Bessette, Lily G.
    Paik, Julie M.
    Najafzadeh, Mehdi
    Brodovicz, Kimberly G.
    Deruaz-Luyet, Anouk
    Schneeweiss, Sebastian
    DIABETES OBESITY & METABOLISM, 2022, 24 (03): : 442 - 454
  • [7] Effectiveness and safety of empagliflozin in routine care patients: interim results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study
    Patorno, E.
    Pawar, A.
    Bessette, L.
    Franklin, J.
    Najafzadeh, M.
    Wexler, D.
    Deruaz-Luyet, A.
    Brodovicz, K.
    Schneeweiss, S.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S145 - S146
  • [8] Effectiveness and Safety of Empagliflozin in Routine Care Patients: Interim Results from the EMPagliflozin compaRative effectiveness and SafEty (EMPRISE) Study
    Patorno, Elisabetta
    Pawar, Ajinkya
    Bessette, Lily G.
    Franklin, Jessica
    Najafzadeh, Mehdi
    Wexler, Deborah J.
    Deruaz-Luyet, Anouk
    Brodovicz, Kimberly
    Schneeweiss, Sebastian
    DIABETES, 2020, 69
  • [9] Comparative Safety of Empagliflozin in Routine Care Patients: Interim Results from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study
    Patorno, Elisabetta
    Tesfaye, Helen
    Wexler, Deborah J.
    Glynn, Robert
    Najafzadeh, Mehdi
    Bessette, Lily G.
    Zakoul, Heidi
    Koeneman, Lisette
    Deruaz-Luyet, Anouk
    Schneeweiss, Sebastian
    DIABETES, 2021, 70
  • [10] Effectiveness and safety of empagliflozin in routine care in Europe and East Asia: results from the empagliflozin comparative effectiveness and safety (EMPRISE) study
    Karasik, A.
    Lanzinger, S.
    Tan, E. Chia-Hui
    Yabe, D.
    JungKim, D.
    Sheu, W. H-H
    Melzer-Cohen, C.
    Holl, R. W.
    Ha, K.
    Nystrom, T.
    Niskanen, L.
    Jensen, M. Linnemann
    Kyaw, M. H.
    Nunez, J.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 229 - 230
12345